Medications for Merkel Cell Carcinoma
These are drugs that have been approved by the US Food and Drug Administration (FDA), meaning they have been determined to be safe and effective for use in Merkel Cell Carcinoma.
Found 3 Approved Drugs for Merkel Cell Carcinoma
Bavencio
Generic Name
Avelumab
Bavencio
Generic Name
Avelumab
Form: Injection
Method of administration: Intravenous
FDA approval date: March 23, 2017
Classification: Programmed Death Ligand-1 Blocker
BAVENCIO is a programmed death ligand-1 (PD-L1) blocking antibody indicated for: Merkel Cell Carcinoma (MCC) Adults and pediatric patients 12 years and older with metastatic MCC.
Pembrolizumab
Brand Names
Keytruda QLEX, Keytruda
Pembrolizumab
Brand Names
Keytruda QLEX, Keytruda
Form: Injection
Method of administration: Subcutaneous, Intravenous
FDA approval date: January 15, 2015
Classification: Programmed Death Receptor-1 Blocking Antibody
KEYTRUDA QLEX is a combination of pembrolizumab, a programmed death receptor-1 (PD-1)-blocking antibody, and berahyaluronidase alfa, an endoglycosidase, indicated: Melanoma for the treatment of adult patients with unresectable or metastatic melanoma.
ZYNYZ
Generic Name
Retifanlimab-Dlwr
ZYNYZ
Generic Name
Retifanlimab-Dlwr
Form: Injection
Method of administration: Intravenous
FDA approval date: March 22, 2023
Classification: Programmed Death Receptor-1 Blocking Antibody
ZYNYZ is a programmed death receptor-1 (PD-1)–blocking antibody indicated: Squamous Cell Carcinoma of the Anal Canal (SCAC) in combination with carboplatin and paclitaxel for the first-line treatment of adult patients with inoperable locally recurrent or metastatic squamous cell carcinoma of the anal canal (SCAC).
Showing 1-3 of 3
Not sure about your diagnosis?
Check Your Symptoms
Tired of the same old research?
Check Latest Advances